

REMARKS

By the present amendment, claims 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 21, 22, 23, 24, 32, 34, 35, 36, 39, 40, 41, 42, 43, 44, 45, 46 and 47 have been amended in order to delete multiple dependencies. The Preliminary Amendment does not contain new matter.

Entry of the above preliminary amendment is respectfully requested. Please calculate the claim fee for the application once the amendment has been entered.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

David N. Bell, Danna L. Skea and Phyllis R. Hedge



Micheline Gravelle
Registration No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada
M5H 3Y2

Tel. (416) 364-7311

A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims ?? have been amended as follows:

3. (Amended) A method according to claim 1 [or 2] wherein the first and second culture media contain serum or plasma.
4. (Amended) A method according to claim 1 [, 2 or 3] wherein prior to step (1) the cells in the starting sample are enriched for T cells.
5. (Amended) A method according to [any one of] claim[s] 1 [to 4] wherein prior to step (1) the cells in the starting sample are enriched for CD4⁺ cells.
6. (Amended) A method according to [any one of] claim[s] 1 [to 5] wherein prior to step (1) the cells in the starting sample are depleted of CD14⁺, CD16⁺, CD19⁺, CD56⁺ and glycophorin A⁺ cells.
7. (Amended) A method according to [any one of] claim[s] 1 [to 6] wherein prior to step (1) the cells in the starting sample are depleted of TcR $\alpha\beta$ ⁺ T cells.
8. (Amended) A method according [to any one of] claim[s] 1 [to 7] wherein prior to step (1) the cells in the starting sample are depleted of non-TcR $\gamma\delta$ ⁺ T cells.
9. (Amended) A method according to [any one of] claim[s] 1 [to 8] wherein the starting sample is selected from peripheral blood, bone marrow, lymphoid tissue, epithelia, thymus, liver, spleen, cancerous tissue, infected tissue, lymph node tissue or fractions thereof.
11. (Amended) A method according to [any one of] claim[s] 1 [to 10] wherein the starting sample is low density mononuclear cells.
12. (Amended) A method according to [any one of] claim[s] 1 [or 3 to 10] wherein in the first culture medium the T cell mitogen is present in an amount from about 0.01 to about 100 $\mu\text{g/ml}$; the IL-2 is present in an amount from about 0.1 to about 1000 ng/ml and the IL-4 is present in an amount from about 0.1 to about 1000 ng/ml.
13. (Amended) A method according to [any one of] claim[s] 1 [or 3 to 10] wherein in the first culture medium the T cell mitogen is present in an amount from about 0.1 to about 50 $\mu\text{g/ml}$; the IL-2 is present in an amount from about 1 to about 100 ng/ml and the IL-4 is present in an amount from about 1 to about 100 ng/ml.
14. (Amended) A method according to [any one of] claim[s] 1 [or 3 to 10] wherein in the first culture medium the T cell mitogen is present in an amount from about 0.5 to about 10 $\mu\text{g/ml}$; the IL-2 is present in an amount from about 2 to about 50 ng/ml and the IL-4 is present in an amount from about 2 to about 50 ng/ml.

15. (Amended) A method according to [any one of] claim[s] 1 [or 3 to 14] wherein the first culture medium comprises 1 µg/mL of a T cell mitogen; 10 ng/mL IL-2 and 10 ng/mL IL-4.
16. (Amended) A method according to [any one of] claim[s] 1 [or 3 to 14] wherein the T cell mitogen is concanavalin A.
21. (Amended) A method according to [any one of] claim[s] 1 [to 20] wherein in the second culture medium the IL-2 is present in an amount from about 0.1 to about 1000 ng/ml and the IL-4 is present in an amount from about 0.1 to about 1000 ng/ml.
22. (Amended) A method according to [any one of] claim[s] 1 [to 20] wherein in the second culture medium the IL-2 is present in an amount from about 1 to about 100 ng/ml and the IL-4 is present in an amount from about 1 to about 100 ng/ml.
23. (Amended) A method according [to any one of] claim[s] 1 [to 20] wherein in the second culture medium the IL-2 is present in an amount from about 2 to about 50 ng/ml and the IL-4 is present in an amount from about 2 to about 50 ng/ml.
24. (Amended) A method according [to any one of] claim[s] 1 [to 23] wherein the second culture medium comprises 10 ng/mL IL-2 and 10 ng/mL IL-4.
32. (Amended) A cell preparation enriched in TcRγδ⁺ T cells prepared according to the method [of any one] of claim[s] 1 [to 28].
34. (Amended) A cell preparation according to claim[s] 32 [or 33] wherein greater than 80% of the total cells are TcRγδ⁺ T cells.
35. (Amended) A cell preparation according to claim[s] 32[, 33 or 34] wherein greater than 90% of the total cells are TcRγδ⁺ T cells.
36. (Amended) A cell preparation according to [any one of] claim[s] 32 [to 35] which comprises Vδ1⁺ and Vδ2⁺ TcRγδ⁺ T cells.
39. (Amended) A use of a cell preparation according to [any one of] claim[s] 32 [to 38] to prepare a medicament to modulate an immune response.
40. (Amended) A use of a cell preparation according to [any one of] claim[s] 32 [to 38] to prepare a medicament to treat an infection.
41. (Amended) A use of a cell preparation according to [any one of] claim[s] 32 [to 38] to prepare a medicament to treat cancer.
42. (Amended) A use of a cell preparation according to [any one of] claim[s] 32 [to 38] to prepare a medicament to treat chronic myelogenous leukemia.

A

- A